Research, Innovation & Clinical Trials
At the contemporary convergence of health, science and engineering and empowered by digital technology, Precinct researchers, clinicians and companies collaborate at the cutting-edge of innovation.
This modern, multi-disciplinary approach positions the GCHKP to deliver next-generation medicine and advanced manufacturing, and comprehensive innovation in preventative health care.
Personalised medicine
A brave new world
Leading-edge micro and nano science, together with 3D printing technology support the development of ground breaking new biomedical devices implants and diagnostic tools in a brave new world of personalised medicine.
The latest in medical imaging technology combines with big data to enable bio-mechanical engineers to personalise training, prevent injury, design rehabilitation and model orthopaedic surgery.
The ‘personalised digital human’ or ‘digital twin’ is fast moving from dream to reality.
Glycomics
A new frontier
Biomedical researchers at the new drug discovery frontier of Glycomics hope to wipe out the global scourge of malaria – full human clinical trials of a promising vaccine are set to commence after a pilot human study proved safe and successful, with a range of infectious diseases and cancers firmly in their sights.
The world-leading Institute of Glycomics currently has two drug and two vaccine technologies in clinical trials.
Clinical Trials
New treatments
Leading the way in clinical trials for neurological devices, clinicians pioneer life-saving procedures to pull blood clots out of stroke patient’s brains, from the inside out, and treat deadly brain aneurisms.
And they’re collaborating with 3D printing specialists to develop surgical models to train specialists from around the world.
Beyond chronic disease and injury
New hope
A team of researchers is preparing for future clinical trials combining 3D spinal regenerative cell therapy with specialised high-tech ‘thought control’ rehabilitation to repair spinal cord damage, giving hope for paraplegics and quadriplegics, while others are closing in a method of accurately diagnosing Chronic Fatigue Syndrome (ME) as they advance treatments for the debilitating disease.
Beyond Innovation
Our world-class people
The GCHKP boasts more than 1000 researchers and 700 research students, along with internationally regarded clinicians and global companies operating in innovative partnerships with researchers and clinicians.
Research Centres & Institutes
The Precinct is home to a number of leading research institutes, spanning life sciences, health, environmental research and urban planning, ICT, advanced manufacturing, engineering and micro and nano-technology.
Clinical Trials
Clinical trials span new drugs and vaccines - including a world-first human clinical trial for a Malaria vaccine - to other therapeutic treatments and medical and diagnostic devices. Clinical trials are conducted at Griffith University, Gold Coast University Hospital, Gold Coast Private Hospital and in collaboration with commercial partners.
Projects
A number of projects are developing new research and collaboration facilities, including Griffith's industry-focused Advanced Design and Prototyping Technologies Institute (ADaPT); a unique integrated child health, development and research facility (Centre of Growth); and a not-for-profit innovation hub exploring artificial intelligence in healthcare (Intelli-HQ).
Equipment & Facilities
Research and testing facilities in the GCHKP span the full spectrum across clinical and biomedical laboratories, industrial and engineering labs, access to specialised micro and nano-technology clean room facilities, and advanced 3D printing and design laboratories, including a new 3D metal printer with titanium printing capabilities (medical-grade).
Commercial partnerships
Researchers and clinicians are commercially focused, with collaborations ranging from joint grant projects to lead roles in multi-site clinical trials and major commercial technology licensing deals. For example, Griffith's Institute for Glycomics is partnering with Chinese pharmaceutical, Olymvax Biopharmaceuticals Inc. to develop a vaccine to prevent Streptococcus A infection.
World's largest commercial glycan array
